OKLO · Oklo Inc. — research history

Oklo is a pre-revenue SMR developer with zero commercial plants operational and no binding power purchase agreements. The company has made genuine regulatory progress—DOE PDSA approval for Aurora-INL (June 2025) is real—but it remains years from revenue generation. Recent ARMEC acquisition (June 8, 2026) adds precision manufacturing capability but is immaterial to near-term financials of a sub-$10B market cap entity burning $50M+ per quarter in operating expenses. The stock is down ~55% YTD and trades ~70% off its 52-week high following the 2025 SMR hype peak, creating a narrative trap: it looks cheap on paper relative to October 2025 peaks, but valuation metrics (forward P/E of -68.9, negative EV/EBITDA) are meaningless for a company with no revenue. Insiders are not buying in open-market transactions—they are receiving RSU grants that vest and generate sales. Options flow is heavily bearish (put/call ratio 3.2, $344K whale put at $90 strike). The core thesis requires the stock to hold above dilution-adjusted cost basis while the company navigates regulatory, fuel supply chain, construction, and financing risks simultaneously—all with no commercial reference plant.

Oklo is a pre-revenue advanced fission reactor developer with $2.2B in cash but -$100M+ quarterly FCF burn and zero commercial powerhouses constructed. The trigger was 3 recent Form 4 filings, all of which turned out to be systematic SELLING (code S) via pre-established Rule 10b5-1 plans by CEO Jacob DeWitte, COO Caroline Cochran, and CLO William Goodwin — not discretionary open-market buys. This is a bearish smart-money signal, not bullish as the trigger implied. The stock has collapsed ~62% from its $193 peak to $73.47 (YTD -44%) following prior dilution via two $1B+ ATM programs in 2025-2026. Legitimate catalysts exist: DOE Surplus Plutonium Utilization program selection, Meta prepayment agreement for a Pike County campus, and Aurora-INL receiving full DOE authorization pathway approval. However, all revenue-generating milestones are multi-year (first powerhouse target: 2028), no binding PPAs have been signed, HALEU fuel supply chains remain constrained, and the company is deeply loss-making with negative FCF in every period.

Massive insider selling ($22.5M) paired with a new $1B ATM offering on top of $3B raised in two years creates an insurmountable dilution overhang. The company is pre-revenue with accelerating losses, triggering a going-concern flag that makes any long or income structure prohibitively risky.

Oklo is a pre-revenue advanced nuclear fission reactor developer with no operating power plants, deeply negative earnings (Q1 2026 net loss: $33M vs $9.8M YoY), and a pattern of massive share dilution via ATM offerings ($3B raised in roughly two years). The pipeline trigger incorrectly labeled insider Form 4 activity as 'open-market purchases' — all three recent Form 4 filings are actually pre-scheduled 10b5-1 SELL transactions by CEO DeWitte (~14M), COO Cochran (~7M), and CFO Bealmear (~$1.13M). Simultaneously, the company filed an $1B new ATM offering on May 13, 2026 after depleting a prior $1.5B facility. The nuclear regulatory catalyst thesis is real but multi-year; there are no near-term revenue catalysts to offset cash burn or dilution risk.

Oklo is a pre-revenue advanced nuclear fission company developing Aurora compact fast reactors (15-75 MWe) with zero operating power plants and no binding customer contracts. The Form 4 cluster triggering this investigation resolved entirely as systematic selling by the CEO, COO, and CFO via Rule 10b5-1 plans adopted in March 2025 — not open-market conviction buys. All insider activity in the past 90 days is S-code sales. Despite a legitimate regulatory catalyst (NRC approved Aurora Principal Design Criteria on May 6, 2026) and high-profile partnerships including Meta and NVIDIA/Los Alamos, the stock trades at ~$12.5B market cap with negative earnings, no revenue, and EPS consistently missing estimates by 60-65%. Options flow is structurally bearish (P/C ratio 2.17). The mispricing/catalyst/edge triad does not hold: there is no defensible intrinsic value case, the NRC approval was already priced in (stock ran +63% prior month), and insiders are net sellers.